Aardvark Therapeutics, Inc. Common Stock
HealthcareNASDAQ:AARD · NASDAQ Global Select
+$0.26 today
Vol 0.13M · Avg 0.20M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-54.0%
avg 13.2%
ROIC
-58.6%
avg -59.9%
ROA
-49.1%
avg -56.3%
Analysis
ROA is currently the strongest return metric at -49.1% versus its period average of -56.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Tien-Li Lee | Chief Executive Officer, Secretary & Director | $973,658.00 | — | 51 | $203,851.00 | 0.93% |
Manasi Sinha Jaiman | Chief Medical Officer | $693,039.00 | — | 45 | $70,549.00 | 0.32% |
Nelson Sun | CFO & COO | $603,300.00 | — | 49 | $70,549.00 | 0.32% |
Zhenhuan Zheng | Chief Research Officer | — | — | — | — | — |
Danny Villeneuve | Chief Commercial Officer | — | — | — | — | — |
Timothy J. Kieffer | Chief Scientific Officer | — | — | 59 | — | — |
Justin T. Stege | VP and Head of Project Management & Strategy | — | — | — | — | — |
Ron Lewis | Vice President & Head of CMC | — | — | — | — | — |
Derrick C. Li | Chief Business Officer | — | — | — | — | — |
Dvorit Samid | Executive Vice President of Medical Affairs | — | — | — | — | — |
Terrie Kellmeyer | Senior Vice President of Regulatory Affairs | — | — | — | — | — |
Christian Zapf | General Counsel | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
8
$450,312.40
Sells
0
$0.00
Net Sentiment
+$450,312.40
Net buying
Most Active
Lee Tien-Li
6 transactions
Analysis
Insiders reported 8 buys worth $450,312.40 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $450,312.40. Lee Tien-Li was the most active insider with 6 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Assembly Biosciences, Inc.
NASDAQ:ASMB
$364.90M
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
$284.66M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
$276.28M
Foghorn Therapeutics Inc.
NASDAQ:FHTX
$245.42M
Zura Bio Limited
NASDAQ:ZURA
$240.58M
Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRX
$202.22M
Avalo Therapeutics, Inc.
NASDAQ:AVTX
$166.70M
Caribou Biosciences, Inc.
NASDAQ:CRBU
$158.19M
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
$118.59M
Pyxis Oncology, Inc.
NASDAQ:PYXS
$111.51M
Who manages AARD?
Aardvark Therapeutics, Inc. Common Stock (AARD) lists 12 active executives. The top listed executive is Zhenhuan Zheng, Chief Research Officer.
Are AARD insiders buying or selling?
Recent insider activity shows net buying of $9.56M.
Explore More
Continue the stock analysis
Jump to another research area for this company.